Efficacy and safety of mij821 in patients with treatment-resistant depression: Results from a randomized, placebo-controlled, proof-of-concept study

INTRODUCTION: MIJ821 is a novel N-methyl-D-aspartate (NMDA) receptor antagonist, with a potentially low rate of the psychotomimetic side effects that limit the therapeutic utility of ketamine in treatment-refractory depression (TRD). OBJECTIVES: To assess efficacy and safety of MIJ821. METHODS: Adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghaemi, N., Sverdlov, A., Shelton, R., Litman, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471356/
http://dx.doi.org/10.1192/j.eurpsy.2021.897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471356/
http://dx.doi.org/10.1192/j.eurpsy.2021.897

Ejemplares similares